No disclosed relationships extracted for ERNAyet. The EDGAR pass hasn't reached this filing; the graph grows as filings are read.
Brooklyn ImmunoTherapeutics, Inc., a clinical stage biopharmaceutical company, engages in developing therapies to treat patients with cancer. Its advanced program is IRX-2 that is in a Phase 2b clinical trial in patients with squamous cell cancer of the head and neck. The company also develops therapies using gene-editing and cell therapy technology for the treatment of oncology, blood disorder, and monogenic disease. Brooklyn ImmunoTherapeutics, Inc. is based in Brooklyn, New York.
Nothing on the wire mentions ERNA yet. Iris sweeps the public feeds every quarter hour; headlines land here the moment a sweep tags them.
How ERNA has moved on past release days vs its typical ±5.1% day, and how often it closed up. Computed from daily closes — not a forecast.